Resistance to ocular antibiotics: an overview

REFERENCES

• AIHW 2005. Mortality over the twentieth century in Australia: Trends and patterns in major causes of death. Mortality Surveillance Series no. 4. AIHW cat. no. PHE73. Canberra, Australia: Australian Institute of Health and Welfare, 2005.
   Google Scholar
• http://nobelprize.org/nobel_prizes/nobelprize_facts.html
   Google Scholar
• Petri WA Jr. Antimicrobial agents (continued). Penicillins, cephalosporins and other β‐lactam antibiotics. In: Hardman JG, Limbird LE, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 10th ed. New York, NY: McGraw‐Hill Companies, Inc, 2001. p 1189–1218.
   Google Scholar
• Salyers AA, Whitt DD. Revenge of the microbes: how bacterial resistance is undermining the antibiotic miracle. Washington DC: ASM Press, 2005.
   Google Scholar
• Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale’s Pharmacology, 6th ed. Edinburgh: Churchill Livingstone Elsevier, 2007. p 647–678.
   Google Scholar
• Rice LB. Antimicrobial resistance in gram‐positive bacteria. Am J Infect Control 2006; 34: S11–S19.
   PubMed Web of Science ®Google Scholar
• Gould IM. Costs of hospital‐acquired methicillin‐resistant Staphylococcus aureus (MRSA) and its control. Int J Antimicrob Agents 2006; 28: 379–384.
   PubMed Web of Science ®Google Scholar
• Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Med 2006; 119: S3–S10.
   PubMed Web of Science ®Google Scholar
• Hawkey PM. The origins and molecular basis of antibiotic resistance. BMJ 1998; 317: 657–660.
   PubMed Web of Science ®Google Scholar
• Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature 2000; 406: 775–781.
   PubMed Web of Science ®Google Scholar
• Choi S‐H, Woo JH, Lee JE, Park SJ, Choo EJ, Kwak YG, Kim M‐N, Choi M‐S, Lee NY, Lee BK, Kim NJ, Jeong J‐Y, Ryu J, Kim YS. Increasing incidence of quinolone resistance in human non‐typhoid Salmonella enterica isolates in Korea and mechanisms involved in quinolone resistance. J Antimicrob Chemother 2005; 56: 1111–1114.
   PubMed Web of Science ®Google Scholar
• Srinivasan VB, Virk RK, Kaundal A, Chakraborty R, Datta B, Ramamurthy T, Mukhopadhyay AK, Bhosh A. Mechanism of drug resistance in clonally related clinical isolates of Vibrio fluvalis isolated in Kolkata, India. Antimicrob Agents Chemother 2006; 50: 2428–2432.
   PubMed Web of Science ®Google Scholar
• Ge B, Mcdermott PF, White DG, Meng J. Role of efflux pumps and topoisomerase mutations in fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother 2005; 49: 3347–3354.
   PubMed Web of Science ®Google Scholar
• Saito R, Sato K, Kumita W, Inami N, Nishiyama H, Okamura N, Moriya K, Koike K. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone‐resistant clinical isolates of Proteus mirabilis. J Antimicrob Chemother 2006; 58: 673–677.
   PubMed Web of Science ®Google Scholar
• Cirz RT, Romesberg FE. Induction and inhibition of ciprofloxacin resistance‐conferring mutations in hypermutator bacteria. Antimicrob Agents Chemother 2006; 50: 220–225.
   PubMed Web of Science ®Google Scholar
• Jana S, Deb JK. Molecular targets for design of novel inhibitors to circumvent aminoglycoside resistance. Current Drug Targets 2005; 6: 353–361.
   Web of Science ®Google Scholar
• Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis. Ophthalmology 1999; 206: 1313–1318.
   Google Scholar
• Tuft SJ, Matheson M. In vitro antibiotic resistance in bacterial keratitis in London. Br J Ophthalmol 2000; 84: 687–691.
   Web of Science ®Google Scholar
• Chalita MR, Höfling‐lima AL, Paranhos A Jr, Schor P, Belfort R. Shifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years. Am J Ophthalmol 2004; 137: 43–51.
   PubMed Web of Science ®Google Scholar
• Morrissey I, Burnett R, Viljoen L, Robbins M. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001–2002. J Infection 2004; 49: 109–114.
   PubMed Web of Science ®Google Scholar
• Marangon FB, Miller D, Muallem MS, Romano AC, Alfonso EC. Ciprofloxacin and levofloxacin resistance among methicillin‐sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol 2004; 137: 453–458.
   PubMed Web of Science ®Google Scholar
• Kotlus BS, Wymbs RA, Vellozzi EM, Udell IJ. In vitro activity of fluoroquinolones, vancomycin, and gentamicin against methicillin‐resistant Staphylococcus aureus ocular isolates. Am J Ophthalmol 2006; 142: 726–729.
   Web of Science ®Google Scholar
• Shanmuganathan VA, Armstrong M, Bulkler A, Tullo AB. External ocular infections due to methicillin‐resistant Staphylococcus aureus (MRSA). Eye 2005; 19: 284–291.
   PubMed Web of Science ®Google Scholar
• Fukuda M, Ohashi H, Matsumoto C, Mishima S, Shimomura Y. Methicillin‐resistant Staphylococcus aureus and methicillin‐resistant coagulase‐negative Staphylococcus ocular surface infection efficacy of chloramphenicol eye drops. Cornea 2002; 21 (Suppl): S86–S89.
   Google Scholar
• Kodsi S. Community‐acquired methicillin‐resistant Staphylococcus aureus in association with chronic dacryocystitis secondary to congenital nasolacrimal duct obstruction. J AAPOS 2006; 10: 583–584.
   Web of Science ®Google Scholar
• Leeming JP. Treatment of ocular infections with topical antibacterials. Clin Pharmacokinet 1999; 37: 351–360.
   PubMed Web of Science ®Google Scholar
• Frishman WH, Kowalski M, Nagnar S, Warshafsky S, Sica D. Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension. Focus on β‐adrenergic blockade. Heart Disease 2001; 3: 386–397.
   PubMedGoogle Scholar
• Antibiotic Guidelines version 13, 2006, Therapeutic Guidelines Limited, Ground Floor, 23–47 Villiers Street, North Melbourne, Victoria 3051, Australia (http://www.tg.com.au).
   Google Scholar
• Schlossberg D. Clinical approach to antibiotic failure. Med Clin N Am 2006; 90: 1265–1277.
   PubMed Web of Science ®Google Scholar
• Vicente M, Hodgson J, Massidda O, Tonjum T, Henriques‐normark B, Ron EZ. The fallacies of hope: will we discover new antibiotics to combat pathogenic bacteria in time? FEMS Microbiol Rev 2006; 30: 841–852.
   PubMed Web of Science ®Google Scholar
• Bradley JS, Guidos R, Baragona S, Bartlett JG, Rubinstein E, Zhanel GG, Tino MD, Pompliano DL, Tally F, Tipirneni P, Tillotson GS, Powers JH, Tillotson GS. Anti‐infective research and development‐problems, challenges and solutions. Lancet Infect Dis 2007; 7: 68–78.
   PubMed Web of Science ®Google Scholar